Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer
Дата публикации: 08-07-2026 07:07:00

Evidence for efficacy is based on the results from the POTOMAC study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC5724-06-2026
2FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC013.1329-07-2026
3New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer011.1324-07-2026
4EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin0519-06-2026
5New Combination Therapy Shows Promise for Advanced Bladder Cancer011.1606-08-2026
6FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer011.8510-07-2026
7EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
8EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan0526-06-2026
9EMA Recommends Extension of Therapeutic Indications for Encorafenib0503-07-2026
10FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies014.5912-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 5. Источник: www.esmo.org.